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Abstract
Background: The HLA gene complex encodes three class II isotypes, DR, DQ, and DP. HLA class II molecules are peptide
receptors that present antigens for recognition by T lymphocytes. In antigen presenting cells, the assembly of matched a
and b subunits to heterodimers is chaperoned by invariant chain (Ii). Ii forms a homotrimer with three binding sites for class
II heterodimers. The current model of class II and Ii structure states that three ab heterodimers bind to an Ii trimer.
Methology/Principal Findings: We have now analyzed the composition and size of the complexes of class II and Ii using
epitope tagged class II subunits and density gradient experiments. We show here that class II-Ii oligomers consist of one
class II heterodimer associated with one Ii trimer, such that the DR, DQ and DP isotypes are contained within separate
complexes with Ii.
Conclusion/Significance: We propose a structural model of the class II-Ii oligomer and speculate that the pentameric class
II-Ii complex is bent towards the cell membrane, inhibiting the binding of additional class II heterodimers to Ii.
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Introduction
Major histocompatibility complex (MHC) class II (MHCII)
peptide receptors are sensors on antigen presenting cells (APC) that
alerttheadaptiveimmunesystemtothe presenceofforeign antigens
by presenting them to CD4
+ T cells. To achieve presentation of a
large variety of antigenic peptides, the human MHC (human
lymphocyte antigen, HLA) contains three isotypic loci, DP, DQ,
and DR, each of which encode the a and b subunits that form
heterodimeric MHCII receptors. An extremely high polymorphism
of the MHCII genes creates a large diversity of the receptors.
Following biosynthesis, the MHCII subunits associate with the
chaperone invariant chain (Ii). Ii forms a homotrimer (Ii3) [1–3],
and MHCII glycoproteins bind to a sequence of Ii that occupies
the peptide binding groove of the ab heterodimer [4–6].
Additional interaction sites of MHCII and Ii have been
demonstrated [7–11]. The homotrimeric structure of Ii would
suggest that three MHCII heterodimers assemble with an Ii trimer
to form a nonameric complex, Ii3(ab)3. Indeed, this assumption
was supported by chemical crosslinking experiments with MHCII
complexes that showed a high molecular weight band with an
apparent size of 260 kDa [12–13]. The oligomeric assembly of
MHCII and Ii is a prerequisite for intracellular transport to
endosomes, followed by degradation of Ii and subsequent
acquisition of exogenous peptides [14].
One possible consequence of the nonamer model is that one
complex could contain different DP, DQ, or DR isotypes bound to
an Ii homotrimer. Because of technical difficulties involved in
distinguishing the individual isotype subunits, this obvious
prediction has not been conclusively tested to date. Remarkably,
initial experiments in mice have shown exclusive co-isolation of Ii
with the murine MHCII isotypes H-2A or H-2E, but no co-
isolation of these two isotypes with each other [15]. Based on this
observation, we have now examined whether indeed DP, DQ, and
DR are found in the same oligomer with Ii.
In contrast to the MHCII heterodimers, Ii has a short cellular
half-life [16–17]. Apparently as a compensation, Ii is synthesized
at a significantly higher rate than MHCII, which leads to a large
excess of the Ii polypeptide in the endoplasmic reticulum (ER)
[18]. Since a stochastic assembly of MHCII subunits with Ii would
therefore yield mostly pentameric complexes (with one MHCII
heterodimer per Ii3), the formation of Ii3(ab)3 nonamers would
require cooperative binding of MHCII ab heterodimers to Ii3.
However, in vitro studies with soluble MHCII and Ii have suggested
that complex formation is not sufficiently cooperative [19].
In recent years, novel methods have been employed to assess the
stoichiometry of the murine cd T cell receptor and of the B cell
antigen receptor [20–21]. These reports have yielded unpredicted
results regarding the ratio of the antigen receptors to their
associated signalling molecules and have thus led to the revision of
previous models.
In this work, we have employed epitope-tagged MHCII molecules
to identify individual subunits of MHCII-Ii oligomers and to examine
their stoichiometry. In transfected APCs, we have also studied the
association of the tagged MHCII subunits with endogenous MHCII
chains. We find that DP, DQ, and DR molecules are not co-isolated
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simultaneously contained in one complex with Ii. In a parallel
approach, immunoprecipitation of DQ from separated MHCII-Ii
complexes did not result inisolation of additional DR heterodimersas
the nonamer model would suggest. To directly determine the size of
DR-Ii complexes, we have estimated the size of the oligomer by
ultracentrifugation on a sucrose gradient to be approximately 130 to
160 kDa. We thus present a pentamer model where only one single
DR, DQ, or DP heterodimer is contained in a MHCII-Ii complex
and propose a conformational change induced upon binding of one
MHCII heterodimer to the Ii3 that could explain why class II
molecules do not abundantly occupy all three CLIP sequences
contained in the Ii3 complex.
Results
Size separation of DR and of Ii complexes
In order to assess the molecular weight of cellular complexes
of endogenous Ii and MHCII molecules, we prepared lysates
from Raji cells, separated the solubilized proteins on a sucrose
density gradient, and detected DRa by western blotting. The
DRa band appeared in fractions 6 to 16 (Fig. 1B). A
densitometric scan of the blot shows two peaks (Fig. 1B, lower
panel) that correspond to molecular weights of 40–70 (fractions 7
to 9) and of 130–160 kDa (fractions 13 to 15), respectively, as
determined by protein standards (Fig. 1A). The double band
seen in fractions 12 to 16 of Fig. 1B is due to differential
carbohydrate processing of the DRa glycoprotein, which was
assessed by EndoH treatment of the DRa glycoprotein (data not
shown). The lower band represents the endoplasmic reticulum
(ER) form of the MHCII subunit, and the upper band contains
DRa with complex type carbohydrates.
In order to test whether separation of MHCII complexes is also
achieved in primary cells, we used lysates of monocyte-derived
dendritic cells (DC) for separation in a sucrose gradient. Fig. 1C
shows a western blot of 24 fractions of sucrose gradient separated
DC lysates. The scan of the DRa western blot reveals two peaks,
similar to the result obtained with Raji cell extracts in Fig. 1B.
Figure 1. Separation of cell extracts on a sucrose gradient by ultra-centrifugation. Cell lysates were ultra-centrifugated on a 0.4 to 0.8 M
sucrose gradient at 100 000 g for 50 h. A) The sucrose concentrations of the fractions were determined after ultracentrifugation by a refractometer
(upper panel). In a parallel tube, molecular weight standards were separated (lower panel). The SDS-PAGE separated protein standards were stained
with Coomassie blue. The peak positions of the separated molecular weight markers are indicated by arrows. IgG bands (insert) are shown in fractions
14 and 15. B) Twenty four samples, obtained from the fractions of the sucrose gradient of Raji cell lysates were boiled in SDS sample buffer and
analysed by SDS-PAGE and subsequent western blotting with monoclonal antibody TAL-1B5 against DRa (upper panel). C) Cell lysates from
monocyte-derived human dendritic cells separated by the sucrose gradient were western blotted for DRa. The positions of DRa and of a protein
standard (34 kDa) are indicated by arrows. The lower panels of B and C show densitometric scans of the western blots.
doi:10.1371/journal.pone.0017257.g001
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bound DR molecules, fractions were treated with sodium dodecyl
sulphate (SDS) at room temperature prior to SDS-PAGE, since DR
heterodimers with a bound peptide resist SDS-induced dissociation
under these conditions [22]. An SDS-resistant band at ca. 55 kDa,
corresponding to peptide-loaded DRab complexes (pDRab), was
indeed observed in fractions 7 to 9 (Fig. 2A). No pDRab band was
detected beyond fraction 11, indicating that this range of the gradient
contains no peptide-loaded DR heterodimers. This suggests that
fractions 13 to 15 contain the complexes of peptide-free DR with Ii.
To further examine the composition of the separated DR complexes,
we next subjected the gradient fractions to immunoprecipitation with
anti-DR monoclonal antibodies. The anti-DR monoclonal antibody
16.23, which reacts with DRab heterodimers but not with DR-Ii
oligomers [23], only immunoprecipitates DR from fractions 7 to 9
(Fig. 2B). In contrast, the conformation-dependent monoclonal
antibody ISCR3 immunoprecipitates DR from both peaks (Fig. 2C),
demonstrating the presence of DRab dimers.
We next probed SDS-PAGE separated fractions for Ii and again
found two peaks, in fractions 8 to 11 and 13 to15 (Fig. 3A). In
contrast, blotting of the DR immunoprecipitates for Ii (Fig. 3B)
resulted ina single peak at fractions 13 to15,which therefore contains
the DR-Ii oligomer. No signal for Ii was obtained in fractions 6 to 11,
suggesting that in the low molecular weight range of the gradient, Ii is
present but not associated with the DRab heterodimer. Immuno-
precipitation of sucrose gradient separated DC lysates with a
monoclonal antibody to DR and subsequent blotting for Ii showed
again that Ii was only detected in fractions 13 to 16 (data not shown),
indicating that these fractions contain DR-Ii complexes.
The results of the sucrose gradient experiments are summarized
in Fig. 3C. The pDRab complex displays the lowest mobility of
the examined complexes (fractions 7 to 9). The low molecular
weight peak of the Ii western blot (Fig. 3A), is found in fractions 8
to 11, slightly heavier than the pDRab complex (Fig. 2A) and it
may represent Ii3. The peaks of pDRab and Ii3 overlap to a great
extent, since molecules of this size are not completely separated on
this sucrose gradient. Crucially, however, even though DR and Ii
are both present in this region of the gradient, no interaction
between them can be detected. The high molecular weight peak of
DR in Fig. 2C and the peak of the DR-Ii complex in Fig. 3B both
most likely represent the DRabIi oligomer. This complex
comigrates with immunoglobulin G (150 kDa), which suggests
that is significantly smaller than the estimated molecular weight of
the postulated nonameric complex (DRab)3(Ii)3, 260 kDa [12].
Remarkably, the amount of oligomeric DR-Ii is lower than the
amount of DRab heterodimers. From the density scans in Fig. 1B
and Fig. 2C, we estimate that under the steady state conditions of
this experiment, roughly one third of the DR molecules in the cell
are contained in DR-Ii complexes.
Assessment of DR and Ii oligomers by chemical
crosslinking
To demonstrate association between DR and Ii in an
independent experimental system, Raji cell lysates were separated
Figure 2. SDS-PAGE separation of Raji cell extracts from sucrose gradient fractions. The lower panels depict densitometric scans of the
western blots. A) Samples treated with SDS sample buffer at room temperature were SDS-PAGE separated and immunoblotted for DRa (monoclonal
antibody TAL-1B5). The upper panel shows SDS resistant pDRab bands (ca. 55 kDa) in fractions 6 to 11. The Scan represents both the pDRab and the
DRa bands. B) Immunoprecipitation (IP) of DRab with monoclonal antibody 16.23, and western blotting for DRa (upper panel). The monoclonal
antibody 16.23 selectively immunoisolates DR from fraction 6 to 10 and shows no reactivity to DR in fractions 11 to 17. C) Immunoprecipitation from
sucrose gradient fractions 6 to 17 with DR monoclonal antibody ISCR3. SDS-PAGE separation and western blotting for DRa (monoclonal antibody
TAL-1B5) results in separation of two DR populations, which is visualized as two separate curves in the density scan.
doi:10.1371/journal.pone.0017257.g002
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molecular weight peaks of DR in Fig. 1B were treated with the
chemical crosslinker, 3,39- dithiobis [succinimidyl propionate]
(DSP) and separated by SDS-PAGE followed by immunoblotting
for DRa or for Ii (Fig. 4A). At low concentrations of DSP, DRa
from fractions 14/15, which contain the DR-Ii complex, remains
monomeric, but at 100 and 200 mg/ml DSP, it shifts to a high
molecular weight band that appears on top of the gel (Fig. 4A
bottom left panel).
The crosslinking of DR from fractions 7/8 (which correspond to
peptide-bound DR molecules) with increasing concentration of
DSP converts the DRa monomer into a band that has the
expected size of the DRab dimer (55 kDa; Fig. 4A, top left panel).
No other bands were detected suggesting that DR crosslinking in
these fractions is specific and does not result in the crosslinking of
DR to other cellular proteins. In striking contrast, blotting of the
same crosslinked fractions for Ii yielded a smear of high molecular
weight material at the top of the gel at 100 and 200 mg/ml of DSP,
while monomeric, dimeric, and trimeric Ii appear as distinct bands
(top and bottom, right panels). With increasing DSP concentra-
tion, Ii3 (95 kDa) becomes abundant, and in fractions 14/15
(which contain the DR-Ii complex), high molecular weight
material accumulates above the Ii trimer and, at 200 mg/ml
DSP, appears as a compact band at the very top of the gel.
Importantly, we noted that even in the absence of association with
DR, in fractions 7/8 (upper right panel), high molecular weight
crosslinks of Ii were formed. This demonstrates that Ii associates
with cellular components other than MHCII, as described
previously [25–30]. Since such additional Ii-interacting proteins
may be contained in all Ii-complexes that are obtained by
chemical crosslinking, it must be assumed that the crosslinked high
molecular weight material that is detected by immunoblotting for
DR and for Ii at the top of the gel (Fig. 4A, lower panels) does not
solely consist of DR and Ii but contains other cellular proteins.
To determine the size of the high molecular weight band that
was obtained upon crosslinking of the DR-Ii complexes, we
separated the crosslinked samples by ultracentrifugation on a
sucrose gradient. We found that DRa bands did not correspond to
a species of uniform size but were almost evenly distributed all
across the high molecular weight area of the gradient (Fig. 4B).
This demonstrates that chemical crosslinking produces DR
complexes with larger size than obtained by separation of
untreated cell lysates in a sucrose gradient (compare Fig. 4B to
Fig. 1B). Presumably, unstable and transient interactions of Ii with
cellular components are stabilized by the crosslinking reagent.
This might have led previous workers to propose a larger apparent
size of the DR-Ii complex.
HLA- DR, DP, and DQ heterodimers segregate into
individual complexes with Ii
If Ii3 associates with more than one MHCII dimer, one would
assume that such complexes contain a mixture of MHCII isotypes
Figure 3. Detection of Ii in sucrose gradient fractions and delineation of DR and Ii complexes. A) SDS-PAGE separated Raji cell extracts
from fractions 1 to 24 and western blotting for Ii (monoclonal antibody Bu43) (upper panel) results in two peaks (scan lower panel). B)
Immunoprecipitation of DR, and SDS-PAGE separation was conducted as in Fig. 2C, followed by immunoblotting for Ii (monoclonal antibody Bu43,
upper panel) and evaluation as a scan (lower panel). The DR-associated Ii appears in lanes 12 to 16. C) DR and Ii oligomers displayed in a sceme.
Peptide-loaded DR (pDRab) largely co-migrates in the sucrose gradient with the Ii trimer. Complexes containing DR-Ii are separated in fractions 12 to
16.
doi:10.1371/journal.pone.0017257.g003
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other should be possible. In contrast, if Ii3 and MHCIIab form
pentameric complexes only, such co-isolation should not be
possible. We therefore transiently transfected the MHCII- and Ii-
expressing human melanoma cell line MelJuSo with cDNA
encoding epitope-tagged DPa or DPb chains, lysed the cells and
immunoprecipitated the endogenous DRab heterodimer. The
immunoprecipitates and cell lysates were separated by SDS-PAGE
and immunoblotted for the presence of transfected epitope-tagged
DPa or DPb, or as a control for endogenous DRa and Ii. No co-
isolation of DPa or DPb with DRa was detected, suggesting that
different MHCII isotypes are not associated via Ii (Fig. 5A, lanes 3
and 7).
In the next experiments, we again examined MHCII-Ii
complexes for the presence of two different MHCII isotypes. To
achieve a uniform expression of the transfected cDNA and to
make sure that the transfected MHCII subunits are integrated into
endogenous MHCII-Ii complexes and introduced into the
biosynthetic route of MHCII molecules, we used stably transfected
cell lines. We first demonstrated by carbohydrate maturation,
endosomal localization, and formation of SDS-resistant dimers
that the transgenic MHCII subunits are assembled and transport-
ed together with endogenous MHCII (see Text S1, supporting
information, Fig. S1A, B, C and D). Next, we tested the sensitivity
of the co-isolation experiment. We immunoprecipitated the
transfected V5-tagged MHCII chain and immunoblotted for co-
isolated Ii. The result indicates that a substantial amount of Ii was
co-isolated with the V5-tagged MHCII chain (Fig. S1E), and it
suggests that any additional MHCII isotype heterodimers (which
should be present in the same complex according to the nonamer
model) should be readily detectable. Since this was not the case in
the above experiment (Fig. 5A), we conclude that in our
experimental system, nonameric Ii3(ab)3 complexes with mixed
isotypes most likely do not exist.
To make sure that a potential nonameric complex of MHCII
and Ii had not been partially disrupted by the use of the detergent
Triton X-100, we decided to test the stability of MHCII-Ii
complexes in other detergents, especially the mild detergent
digitonin. Ii was immunoprecipitated from a digitonin cell lysate
and bound to Protein G Sepharose. This Ii-immunoprecipitate
(which according to the nonamer model, should contain three
MHCII heterodimers and Ii3) was then incubated with Triton X-
100 to test whether Triton X-100 would release any MHCII
proteins. The immune complexes on the beads and the Triton X-
100 supernatant were then separated on SDS PAGE and
immunoblotted for Ii and for DRa. Fig. S1F shows that Ii and
Figure 4. Chemical crosslinking of DR and of Ii oligomers. DR and Ii oligomers separated by sucrose gradient fractions of Raji cell lysates were
crosslinked with DSP. A) Sucrose gradient fractions 7/8 and fractions 14/15 were analysed in the upper or lower panels. Concentration of DSP is
shown on top. Untreated or crosslinked samples were separated by SDS-PAGE and western blotted for DRa (monoclonal antibody TAL-1B5, left
panels) or for Ii (monoclonal antibody Bu43, right panels). On the right, positions of molecular weight markers are depicted. The dimeric form of Ii
(70 kDa), which is seen both in untreated and in crosslinked samples, is produced by oxidation of a free cysteine residue of Ii to an inter-molecular
disulfide bond [24]. B) Fractions 14/15 were crosslinked with 200 mg DSP/ml. Subsequently, crosslinked proteins were subjected to ultra-
centrifugation on a sucrose gradient, separated by reducing SDS-PAGE followed by immunoblotting for DRa.
doi:10.1371/journal.pone.0017257.g004
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was detected in the Triton X-100 supernatant. This result
indicates that Ii-DR complexes were stable in Triton X-100 and
that in digitonin and Triton X-100 lysates, identical amounts of
DR are associated with Ii. Thus, Triton X-100 induced
dissociation is not an explanation for the lack of detection of
nonameric Ii3(ab)3 complexes.
According to the nonamer model, it should be possible to co-
immunoprecipitate different MHCII isotypes that are bound to Ii
in the nonameric complex directly with each other. To test this
assertion, we next examined whether endogenous DR could be
precipitated from the lysate of MelJuSo in a complex with stably
expressed DPb tagged with the V5 epitope (DPbV5). DP or DR
molecules were immunoprecipitated and immunoblotted for
DPbV5 or for DRa, respectively. We found that immunoprecip-
itation of DP and a subsequent western blot for V5 detects DPbV5
(Fig. 5B, lane 1), but not DRa (lane 4; correspondingly, the DR
immunoprecipitate shows a band for DRa (lane 5), but not for
DPbV5 (lane 2). These results suggest that transfected DPb and
endogenous DR chains are not found in the same protein complex
in cells.
Next, we studied the co-isolation of transgenic DQa with
endogenous DRa, hypothesizing that if more than one isotypic
heterodimer is contained in a nonameric complex with Ii, it should
be possible to co-isolate two isotypic a chains. We transfected
MelJuSo cells with a cDNA encoding V5-tagged DQa and, to
examine the functional assembly of this transgenic DQa with the
endogenous b chain, we inspected the maturation of the DQa
chain glycans. DQa chain contains two N-linked carbohydrates
(upon arrival of the MHCII oligomer in the medial Golgi
apparatus, one of the two glycans of the a chain acquires
endoglycosidase H (EndoH) resistance, whereas the other remains
EndoH sensitive). We found that most of DQa acquired partial
EndoH resistance (Fig. 5C), which demonstrates that the
transiently expressed DQa is transported out of the ER.
To assess whether endogenous DRa co-isolates with the
transfected DQaV5, DQaV5 was then immunoprecipitated with
a monoclonal antibody against the V5 epitope. Western blotting of
the immunoprecipitate showed a faint band of endogenous DRa
(Fig. 5C, lane 4), which was completely sensitive to EndoH
treatment (lane 5), indicating that these aggregates of DQ and DR
were transient and did not leave the ER. It is important to
emphasize that the amounts of DRa co-isolated with DQaV5 are
traces of bands at the limit of detection.
For comparison to lanes 1 to 3, glycosidase-treated lysates of
MelJuSo cells were blotted for DRa (lanes 7 to 9). In conclusion,
the results in Figure 5 indicate that the post-ER forms of DR, DQ
and DP glycoproteins are not co-isolated from MelJuSo cell
Figure 5. Inspection for co-isolation of DP and DQ isotypes with DR. A) MelJuSo cells were transiently transfected with cDNAs encoding V5-
tagged DPa or DPb encoding cDNAs. Cells lysed in 1% NP40 were immunoprecipitated for DRab (monoclonal antibody ISCR3) (lanes 1,2,3,5,6 and 7).
Lanes 4 and 8 contain cell lysates. The SDS-separated polypeptides were immunoblotted for DRa (lanes 1 and 5), for Ii (lanes 2 and 6), and for DPaV5
(lanes 3 and 4), or for DPbV5 chains (lanes 7 and 8). The position of DRa, Ii and Ab-epitope tagged DPaV5 or DPbV5 bands is indicated. H and L chain
bands derived from the Ab used for immunoprecipitation are labeled on the left. B) Immunoprecipitates of the V5-tagged DPb (lanes 1 and 4) and of
DRab (lanes 2 and 5) chains were separated by SDS-PAGE and either blotted for DPbV5 (lanes 1 to 3) or for DRa (lanes 4 and 5). To monitor expression
of DPbV5, lane 3 contains cell lysate. The position of DPbV5, of DRa and of H and L Ig chains are indicated. C) MelJuSo cells were transfected with V5-
tagged DQa cDNA. Cell lysate was immunoprecipitated for the V5-tagged DQa chains. Immunoprecipitates (lanes 4 to 6) and cell lysates (lanes 1 to 3)
were digested with EndoH (EH), or with PNGase F (PF) or left untreated (Ø), separated by SDS-PAGE and western blotted as indicated. In lanes 7 to 9
MelJuSo cell lysates untreated and glycosidase treated were western blotted for DRa.
doi:10.1371/journal.pone.0017257.g005
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entirely separate complexes with Ii.
DRab heterodimers form pure isotype complexes with
invariant chain
The existence of such isotype-specific complexes of MHCII and
Ii could be explained in two different ways. Either, an Ii
homotrimer would form a complex with two or three MHCII
heterodimers from one particular isotype only. Alternatively, one
Ii homotrimer would only ever bind one MHCII heterodimer in
total, of whatever isotype, to form a pentameric complex.
To distinguish between these two possibilities, we next
investigated whether the transgenic DRaV5 chain is found in
the same complex with Ii and with endogenous DRa chain. We
hypothesized that if this complex contains several DR heterodi-
mers, it should be possible to detect two DRa chains in a complex
with Ii. We therefore transfected MelJuSo cells with a V5-tagged
DRa chain. Inspection of carbohydrate maturation showed that
the majority of transfected DRa chains was partially EndoH
resistant, indicating that they were assembled with endogenous b
chains and transported beyond the cis-Golgi (Fig. 6A). To
distinguish between endogenous DRa and transfected DRaV5,
we used the DRa-specific monoclonal antibody TAL-1B5, whose
epitope is at the extreme C-terminus of DRa [31]; the extension of
the C-terminus of DRa by the V5 epitope abrogates TAL-1B5
binding (Fig. 6B, lanes 1 and 3). When DRaV5 was immunopre-
cipitated with the anti-V5 antibody and immunoprecipitates were
blotted for co-isolated endogenous DRa with TAL-1B5, only very
faint traces of endogenous DRa were detected (Fig. 6A, right
panel). These very faint bands were entirely sensitive to EndoH
treatment, suggesting weak and transient interactions between
endogenous DRa and transfected DRaV5 in the ER only, but not
at later stations of the intracellular pathway.
To demonstrate separation between endogenous DRaand
transfected DRaV5 in DR-Ii complexes by an independent
experimental approach, we transiently expressed DRaV5, DRa,
DRb, and Ii simultaneously in COS-7 cells (Fig. 6C). DRaV5 was
immunoprecipitated from transfected and from untransfected
COS cells (lanes 1 to 6) and immunoblotted for DRaV5, DRa and
DRb. (As a control, the expression of the transfected cDNAs is
shown in lanes 7 to 10). As before, no DRa was co-
immunoprecipitated with DRaV5 (lane 4), while the DRaV5
chain (lane 2) and the DRb chain (lane 6) were readily detected in
the V5 immunoprecipitates. Taken together, these experiments
demonstrate that DRa and DRaV5 are contained in separate
Figure 6. Isolation of Ab-epitope tagged DRa chains from transfected MelJuSo cells. A) MelJuSo cells transfected with DRaV5 cDNA were
lysed. Cell lysates and V5-immunoprecipitates from cell lysates were digested with EndoH (EH) (lanes 2 and 5), with PNGse F (PF) (lanes 3 and 6), or left
untreated (Ø) (lanes 1 and 4). SDS-PAGE separated cell lysates were immunoblotted for DRaV5 (monoclonal antibody V5) and V5-immunoprecipitated
for DRa (western blotted with DRa monoclonal antibody TAL-1B5). B) Reactivity of monoclonal antibody TAL-1B5 to V5-tagged DRa is abolished.
COS-7 cells were transfected with DRaV5 encoding cDNA. Cell lysate was immunoprecipitated with V5 or with TAL-1B5 (DRa) monoclonal antibodies.
Immunoprecipitates were separated in lanes 1 to 4, and lane 5 contains lysate of MelJuSo cells. Lanes were western blotted as indicated. C) COS-7
cells were transfected with DRaV5, DRa,D R b and Ii encoding cDNAs. Cell lysates from transfected (+) and from non-transfected (2) COS cells were
immunoprecipitated for V5 (lanes 1 to 6). Immunoprecipitates and cell lysates (lanes 7 to 10) were SDS-PAGE separated and western blotted with
mAbs V5 for DRaV5, TAL-1B5 for DRa, LGII-612.14 for DRb, and Bu43 for Ii.
doi:10.1371/journal.pone.0017257.g006
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DRab heterodimer.
An analogous experiment with DRb chain showed no co-
isolation of endogenous DRb with DRbV5, confirming the
observation with DRa (see Text S1, supporting information, Fig.
S2A). In addition, this experiment was repeated with the detergent
digitonin (Fig. S2B). Again, endogenous DRb was not co-isolated
with DRb-V5.
To exclude the possibility that the observed pentameric
complexes were an artefact of transfection, and to verify that
under non-transfected conditions DR and DQ segregate into
individual complexes with Ii, we employed the mAb 1a3, which
reacts with DQ but does not crossreact with DR. We lysed
untransfected Raji cells and separated the lysates on sucrose
gadients as before. In these gradients, the pooled fractions 7/8
contain peptide loaded MHCII heterodimers (e.g. DQab and
DRab heterodimers), and fractions 14/15 harbour MHCII-Ii
complexes (see Fig. 1 to 3). Both pools of fractions were
immunoprecipitated for DQ (Fig. 7, lanes 1 and 2) and for DR
(lanes 3 and 4) and subsequently immunoblotted for DRa (upper
panels) or for DQb or DRb chains (lower panels). Immunopre-
cipitation of DQ from fractions 7/8 (lane 1) shows no reaction
with the DRa mAb (upper panel), confirming that mAb 1a3 does
not crossreact to DR. Staining of DQb (lower panel, lane 1)
indicates that 1a3 immunoprecipitates DQ. When fractions 14/15
were immunoprecipitated for DQ, the DQb chain was detected by
western blotting (lane 2, lower panel). Strikingly, however, no
DRa was coprecipitated with DQ from the gradient fractions
containing MHCII-Ii complexes (lane 2, upper panel). As a
control, immunoprecipitation of DR shows that DRa (upper
panel) and DRb (lower panel) are indeed present in both pools.
This result suggests that in untransfected cells, complexes of DQ
with Ii do not contain DR.
Subunit composition of DR-Ii oligomers
Finally, we wished to analyze the formation of the complexes of
DR and Ii, which occurs soon after biosynthesis in the ER.
DRbV5-transfected MelJuSo cells were pulse labeled with
35S-
methionine for 10 min. (At this short time point, the majority of
labeled MHCII and Ii chains localize to the ER). Cells were then
lysed, and DRbV5 was immunoprecipitated with anti-V5
monoclonal antibody or with the conformation-dependent mono-
clonal antibody I251SB against DRab. To assess the mobility of
the individual polypeptide chains, Ii, DRb,D R a and DRbV5
were immunoprecipitated from lysates of transfected COS-7 cells
(Fig. 8, lanes 1 to 4).
Immunoprecipitation of DRbV5 from lysates of the transfected
cells revealed two bands (Fig. 8, lane 5), but no band for
endogenous DRb, suggesting that as in the steady-state experiment
(Fig. S2), the transfected DRbV5 was not associated with
endogenous DRb via Ii The lower band in lane 5 corresponds
to the mobility of Ii, and the upper band contains both DRa and
DRbV5, as shown by the separation of immunoprecipitates of
lanes 4 and 5 on a long gel (right panel). Lane 5 also indicates that
DRbV5 is not overexpressed in comparison to endogenous DRa.
The results of this experiment suggest that the ER form of the
DRabIi complex contains only one DRb chain and not several.
To rule out that the labeling time (ten minutes), was to short to
allow for the formation of a larger complex, we pulse labeled
DRbV5 expressing cells for 10 minutes with
35S methionine
chased for 40 minutes with unlabeled methionine, and immuno-
precipitated DRbV5 (lane 11). As in lane 5, two bands containing
DRbV5 plus DRa and Ii were separated whereas endogenous
DRb could not be detected. Thus, the complex of DR and Ii
contains only one DRb chain.
A revised model for MHCII-Ii oligomers
Finally, we attempted to reconcile our data with the existing
knowledge of the three-dimensional structure of MHCII and Ii
using a computational model. At first, we considered the structure
of Ii3. The primary sequence of Ii shows a repeat of leucine pairs,
starting at the cytosolic tail at Leu-7 of the Ii 33 kDa form of the
polypeptide. The leucine residues appear in a distance of seven
amino acids and this motif is repeated five times through the
membrane spanning region towards the luminal part up to residue
81, suggesting an extensive interhelical interaction such as a
leucine zipper. Since the three Ii chains are known to interact
within the membrane [32], we postulate that the trimeric domain
of Ii extends from residues Leu-7 to Leu-81. Figure 9 shows a
structural model in which the amino terminus of Ii shows a coiled
structure composed of three Ii subunits, followed by a non-ordered
sequence between amino acid 82 and the C-terminal trimeric
domain. This loop contains the CLIP sequence, which fills the cleft
of the MHCII heterodimer [6]. In the model, the binding of the
CLIP sequence to the MHCII heterodimer is sterically possible in
the complex if one assumes a slightly kinked arrangement of the
MHCII molecule with respect to the membrane. The other two Ii
chains are indicated in the same conformation as that associated
with an MHCII heterodimer. It has been shown that the CLIP
containing segment is disordered in the absence of a bound
MHCII heterodimer [19]. Hence, the segment structure of the two
unbound Ii-chains in the model represents one among several
possible conformations. According to the structural model, binding
of one MHCII molecule would not sterically exclude the possibility
of two other Ii chains to adopt a near-bound conformation of the
CLIP segment. However, consistent with a pentameric structure, it
is possible that binding of one MHCII heterodimer restricts the
conformational freedom of the Ii trimer by introducing a kink in
Figure 7. Isolation of DQ-Ii complexes from sucrose gradient
fractions. Sucrose gradient fractions of Raji cell lysates were subjected
to immunoprecipitation with mAb 1a3 against DQ and with DR mAb
ISCR3. Fractions 7 and 8 or 14 and 15 were pooled and immunopre-
cipitated. DQ (lanes 1 and 2) or DR (lanes 3 and 4) were isolated, and
western blotted for DRa (upper panel, mAb TAL-1B5) or for DQb (lower
panel, lanes 1 and 2) and for DRb (lanes 3 and 4) with mAb LGII-612.14.
The position of DRa,o fD Q b or of DRb and bands corresponding to
immunoglobulin heavy (H) and light (L) chains are labeled by arrows.
doi:10.1371/journal.pone.0017257.g007
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PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e17257Figure 8. Metabolic labeling reveals that only one DRb chain associated to an Ii homotrimer. The composition of DR-Ii complexes in pulse
labeled immunoprecipitates from MelJuSo cells, stably transfected with DRbV5 encoding cDNA. COS cells and MelJuSo cells expressing MHCII
subunits and Ii were pulse labeled for 10 min with
35S-methionine. Cells were lysed and immunoprecipitated for Ii (monoclonal antibody Bu45, lane
1), for DRb (S35, lane 2), for DRa (monoclonal antibody TAL-1B5, lane 3), for DRbV5 (monoclonal antibody V5, lanes 4 and 5), for DRab (monoclonal
antibody I251SB, lanes 6 and 7) and as a control of reactivity of V5 monoclonal antibody with untransfected MelJuSo cell extract (monoclonal
antibody V5, lane 8). Lanes 9 and 10 show molecular weight standards. In lane 11 a DRbV5 immunoprecipitate of MelJuSo cells which were pulse
labeled for 10 min with
35S methionine and subsequently cultured for 40 min with medium containing non-radioactive methionine is shown.
Immunoprecipitates from lanes 4 and 5 (left panel) were separated on a 20 cm long SDS PAGE gel to separate DRbV5 and DRa chains (right panel).
doi:10.1371/journal.pone.0017257.g008
Figure 9. Modeling of MHCII-Ii structure. (left) Molecular model (see Methods section for details) for a pentameric MHCII-Ii oligomer consisting
of a trimeric Ii (chains are in blue, red and green cartoons) and one bound MHC-II heterodimer (alpha and beta chains in pink and brown cartoon,
respectively). The position of the membrane is indicated (bars representing approximately the lipid-solvent boundary). (right) Top view of the model
(from the ER) along the axis of the coiled-coil structure.
doi:10.1371/journal.pone.0017257.g009
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heterodimers.
Discussion
Shortly after biosynthesis in the ER, MHCII a and b chains
form transient aggregates [33]. Expression of Ii enables the release
of a and b chains from such aggregates and facilitates correct
assembly of the MHCII subunits [34]. When assembly is
accomplished, the MHCII-Ii complex exits the ER. The three-
dimensional structure of the MHCII-Ii complex has not yet been
resolved by crystallography or nuclear magnetic resonance, and
thus its composition is still not fully clarified. In the initial report by
Roche et al. [12], the authors concluded from crosslinking
experiments that a band of lower mobility than 220 kDa
molecular weight marker represented the crosslinked DR-Ii
complex, and they hypothesized that the MHCII-Ii complex is
composed of nine subunits, an Ii trimer and three DR
heterodimers, with a total molecular weight of 260 kDa [35]. In
agreement with the original observation by Roche and collabo-
rators, we find that DR indeed crosslinks into high molecular
weight complexes, but we also find that such complexes are of a
very broad size range and that besides Ii (and where applicable,
MHCII) they may contain other cellular components. Our results
indicate that crosslinking experiments alone are not sufficient to
accurately predict the size of the MHCII-Ii complex.
In this study, we have investigated the stoichiometry of MHCII-
Ii complexes by using epitope-tagged subunits of MHCII and
assessing their co-isolation with endogenous components. In
contrast to the work cited above, we find strong evidence for a
pentameric complex consisting of an Ii trimer and one dimer of
MHCII.
Several lines of evidence from the literature support our findings
that Ii forms distinct complexes with the MHCII isotypes. Initial
studies in mice were performed with antisera specific for H-2A or H-
2E isotypes of Ia (mouse MHCII) [15]. Such locus-specific antisera
separately isolated metabolically labeled H-2A and H-2E isotypes
bound to Ii, but did not coprecipitate H-2A with H-2E or vice versa
[36]. The co-isolation of H-2A and H-2E that did occur with some
monoclonal antibodies was found to come from cross-reactivity of the
monoclonal antibodies to the two isotypes [37]. Likewise, in humans,
the cross-reactivity of many anti-HLA-class II monoclonal antibodies
with several of the three isotypes may explain why distinct complexes
of DP, DQ, and DR with Ii have not been clearly demonstrated to
date. We show here that DP or DQ immunoprecipitates do not
contain DR subunits. This result suggests that the Ii trimer only
associates with one of the DP, DQ, or DR isotype heterodimers.
The direct determination of size of the Ii-MHCII complex is
naturally difficult because of the highly elongated nature of Ii,
which leads to an apparent size of twice its molecular mass in gel
filtration and light scattering [2], and because of the association of
detergent with the protein, which might lead to an artefactual
increase in the hydrodynamic radius [38]. Thus, in a combined gel
filtration/sedimentation velocity ultracentrifugation experiment, a
mass of 390 kDa was calculated for the DR-Ii complex [12], with
the deviation of this value from the calculated mass of the
nonameric Ii3(ab)3 complex (260 kD, see above) assigned to
detergent. In our experiments by separation of cell lysates in a
sucrose gradient and comparison to protein standards, we estimate
a molecular weight of about 130 to 160 kDa for the DR-Ii
complex. Here, the sedimentation properties of the protein are not
entirely determined by its association with detergent micelles, since
we can very well separate small DRab from large DRabIi
complexes (Figures 1, 2 and 3).
To investigate whether the use of a different detergent, Triton
X-100, was responsible for our differing size estimate, we
examined two additional detergents, n-octylglycoside and digito-
nin for separation of MHCII complexes in a sucrose gradient. In
our hands, the sucrose gradient with either of these detergents did
not separate peptide loaded MHCII molecules from MHCII-Ii
complexes (data not shown). To show that the use of Triton X-100
did not lead to dissociation of a larger complex, we then
demonstrated that Ii-DR complexes from digitonin-lysed cells
are indeed stable in Triton X-100 (Fig. S1F). We therefore
conclude that Triton X-100, which can be used to separate
MHCII-Ii complexes from Ii free MHCII heterodimers, allows the
isolation of intact and complete Ii-DR complexes.
Nuclear magnetic resonance studies of recombinant soluble Ii
have shown that the MHCII binding site is contained in a
disordered region of Ii [39] that acquires an ordered conformation
upon MHCII binding [19]. In vitro assembly of titrated soluble Ii
with constant amounts of soluble DR (truncated just before the
transmembrane domain) showed additional bands in a non-
denaturing gel at decreasing Ii concentrations. This result was
taken to suggest that Ii oligomers associate with several pairs of
MHCII subunits [19]. Our data, in contrast indicate that only one
full-length MHCII heterodimer is contained in the MHCII-Ii
oligomer, resulting in a pentameric Ii3ab complex.
Our molecular model of the complex (Fig. 9) is not per se
evidence for a pentameric complex, but it conclusively demon-
strates that the pentameric model is compatible with all known
structural data, and it suggests a possible mechanism for unique
binding of a MHCII heterodimer to Ii3. We postulate that upon
binding of a single MHCII heterodimer to one unstructured CLIP
sequence, the triple-helical core domain of Ii3 changes its
conformation, which imposes a steric constraint onto the entire
complex, discouraging binding of further MHCII heterodimers.
Interestingly, the murine MHC class I molecule H-K
b, which is
structurally related to MHCII molecules, was suggested to adopt a
supine (lying down) orientation on the membrane, with the peptide
binding site close to the membrane (while remaining accessible to
the T cell receptor and the CD8 coreceptor [40]). If an MHCII ab
heterodimer adopted a similar conformation, then Ii would need
to bent over extremely strong to interact with them, which would
presumably prevent the binding of a second and third MHCII ab
heterodimer. Conclusive evidence to the nature and degree of the
conformational change of Ii3 upon MHCII ab binding will
probably only be obtained upon the resolution of the three-
dimensional structure of the complex.
Why would Ii itself form a trimer if it does not bind three
MHCII heterodimers? We can offer several hypothetical expla-
nations. First, Ii contains several topogenic sequences in its
cytosolic tail that are responsible for internalization from the cell
surface and for the targeting of the complex to endosomes [41].
Trimerization of Ii is required for the efficient targeting of
MHCII-Ii to endosomal compartments [42–43], suggesting that
the trimeric character allows Ii to fulfil its function in targeting
MHCII to endosomes more efficiently. The trimeric tail could
have a similar function in ER-to-Golgi transport, where COPII
coat of transport vesicles is known to recognize oligomeric
cytosolic tails of proteins, and/or in other intracellular steps
[44–45]. Second, Ii (CD74) plays a role as a cell surface receptor
or coreceptor for a number of proteins, most prominently for the
macrophage inhibitory factor (MIF). Since MIF itself is a trimer
with rotational symmetry, a trimerization of Ii might be required
to bind MIF [27], [46].
A pentameric MHCII- Ii complex has some distinct advantages
for the process of MHCII antigen presentation. First, one would
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domains of Ii, a pentamer would be more sensitive to proteolytic
digestion in the endosome; two of the three Ii molecules would be
rapidly cleaved, leading to the breakup of the Ii3 trimer. In a
nonamer, the protease-resistent MHCII heterodimers would
shield Ii from degradation in endocytic compartments. Second,
in a pentameric complex, ER quality control of MHCII would
probably be faster and more efficient. Usually, two alleles each of
the a and b chains of DP and DQ isotypes are expressed (DRa is
nonpolymorphic). From the numerous combinations of DP, DQ
and DR a and b chains that are present in the ER, only a few can
form matching heterodimers. The quality control in the ER
permits exit of MHCII-Ii oligomers only after assembly of the
matching MHCII chains, while mismatched ab heterodimers do
not exit the ER [47]. The assembly of these matched heterodimers
takes place on Ii3 [48]. If a nonameric complex was formed in the
ER, three matched dimers would have to be found for the complex
to leave the ER [49], whereas association of the Ii trimer with only
one ab heterodimer would allow the immediate exit of a MHCII
molecule from the ER, as soon as it is properly assembled.
Substantial work is required to explore the cell biological
consequences of our findings.
Materials and Methods
Cells, transfection, and biosynthetic labelling
MelJuSo is a human melanoma cell line that expresses large
amounts of HLA class II molecules and Ii. Monocyte-derived DCs
were a kind gift of Dr. S. Koch, Determatology Department,
Bonn. MelJuSo cells, Raji cells and COS-7 cells were cultured in
DMEM containing 10% FCS. Cells were transfected with JetPEI
(QBiogen, Heidelberg, Germany) according to instructions of the
supplier. Briefly, 1 to 2 mg DNA were mixed with 2.5 to 5 ml
JetPEI in 100 ml medium, added to 5610
5 cells, and subsequently
the cells were cultured for three days. For labeling, 2610
6 cells
were suspended in 200 ml RPMI medium without methionine and
100 mCi of
35S methionine were added. After a pulse of 10
minutes, the cells were pelleted by centrifugation and washed with
cold PBS. The pulse labeled cells were chased with medium
containing non-radioactive methionine.
Immunoprecipitation, western blotting, and
immunofluorescence microscopy
Cells were lysed with 1% NP40 or with 1% Triton X-100 in
Tris-buffered saline pH 7.4 containing protease inhibitors (Com-
plete, Roche Diagnostics, Mannheim Germany). DNA and debris
were removed by high speed centrifugation. Pre-absorption of the
lysate was conducted with CL4B-Sepharose (Amersham, Freiburg,
Germany). Immunoprecipitates were isolated with protein A
Sepharose, separated by SDS-PAGE, and blotted onto Immobilon
P membrane (Millipore, Schwalbach, Germany). Immunoblotting
was conducted with primary and secondary antibodies conjugated
with horseradish peroxidase and subsequently visualized with ECL
enhanced chemoluminescence. Western blots were calibrated with
protein standards. To assess sensitivity of the assay, titration
experiments were conducted. We determined that cell lysates of 30
000 cells were sufficient to detect MHCII subunits or Ii. In our
experiment, we used lysates of 1 million cells for IP and 100 000
cells as lysate controls. The exposure time of the western blots was
usually 1 to 5 min. For endoglycosidase treatment, cell lysates
were digested with EndoH (200 U) and with PNGase F (100 U)
overnight at 37uC as recommended by the supplier (NEB Biolabs,
Frankfurt, Germany). For confocal immunofluorescence micros-
copy, cells were seeded on coverslips, fixed with 4% PFA, and
permeabilized with 1% Triton X-100. Cells were labeled with
CD63 Alexa 488 and with V5 monoclonal antibodies followed by
Alexa-594 secondary antibody. Staining was monitored by
confocal-fluorescence microscopy (LSM-510 Meta, Zeiss). The
size of the optical section was 1 mm.
Molecular Modeling
A molecular model of a pentameric MHCII-Ii oligomer
consisting of a trimeric MHCII-Ii and one bound MHCII
heterodimer was generated by combining known experimental
structures of a CLIP peptide in complex with HLA-DR3
(pdb1A6A) [6], the known C-terminal trimerisation domain of Ii
(residues 118 to 216, pdb1IIE, [3]) and a homology model for the
N-terminal coiled-coil structure (residues 7-81) using the
SPDBViewer [50] and the Amber molecular modelling software
[51]. The N-terminal trimeric coiled-coil structure was built using
a known structure (pdb3MO6) as template guided by the leucine
repeats in the Ii N-terminal sequence. The connecting loop
segments between Ii segments were generated with the
SPDBViewer [50]. The subunits were placed manually avoiding
steric overlap and allowing insertion of missing loop segments
between the C-terminal trimerisation domain, the CLIP sequence
and the N-terminal coiled-coil structure employing the loop
builder option in SPDBViewer. It is important to emphasize that
the structural model represents only one sterically possible
structure among many possible alternative loop conformations
and variations in the relative subunit arrangement. The complete
model was finally energy minimized to remove any sterical overlap
employing the Amber package [51].
DNA constructs and antibodies
DPa (DPA1*0103), DPb (DPB1*0401) and DQA1*0103 were
cloned from dendritic cells generated from blood monocytes. The
DP a and b chains were appended with Ab-tags [52]. The DRb
(DRB1 0101) chain was tagged with V5-His epitopes (pcDNA3.1
Invitrogen, Karlsruhe, Germany). DRa and DQb contain
appended V5 epitopes. TAL-1B5 monoclonal antibody [53] is
directed against the cytoplasmic tail of DRa. It was used for
immunoprecipitation and for western blotting. Monoclonal
antibody I251SB [54] is directed against DRab heterodimers. It
does not react with single DR chains. Monoclonal antibodies
ISCR3 and 16.23 against DR have been described previously [55–
56]. Serum 35 (S35) was generated by immunizing a rabbit with a
DRb fusion protein [57]. Monoclonal antibody LGII-612.14
reacts to DR, DP and DQb chains (purchased from Dr. S.
Ferrone, NY). Monoclonal antibody1a3 is specific for DQ and was
purchased from MyBioSource (San Diego, CA). Monoclonal
antibody Bu43 is directed against the C-terminus, Vic-Y1 to the
N-terminus and Bu45 to the trimerisation domain of Ii [58]. V5
and His monoclonal antibodies were purchased from Invitrogen.
Sucrose gradient ultracentrifugation
The sucrose gradient was poured by gradually mixing 0.4 M
with 0.8 M sucrose in 10 mM Tris-buffered saline pH 7.5
containing 0.5% Triton X-100. One ml of Raji cell lysate was
placed on top of the gradient and centrifuged at 100.000 g for
50 h. Twenty-four fractions of the gradient were subsequently
collected from the top of the tube. The sucrose concentration of
the fractions was determined with a refractometer (Fig. 1A. upper
panel). By separation of protein standards and subsequent analysis
of the fractions by SDS PAGE and Coomassie blue staining, a size
calibration of the gradient was achieved (Fig. 1A, lower panel).
The protein standard IgG (m.w. 150 kDa), which defines a region
with higher molecular weight, was identified in fractions 13 to 16
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samples obtained from separation of Raji cell lysates were mixed
with reducing SDS sample buffer, boiled, separated by SDS
PAGE and immunoblotted for DRa. The gradient was repro-
duced in more than ten experiments, showing no more variation
than one fraction.
Chemical crosslinking
To 100 ml of a pool of fractions 7 and 8 or of fractions 14 and 15
of the sucrose gradient (without Tris) separated Raji cell lysates
increasing amounts of the thiol- cleavable crosslinker 3,39-dithiobis
[succinimidyl propionate] (DSP) were added. Samples were
incubated for 2 h on ice. For quenching the excess crosslinker,
10 ml of 1 M Tris was added. Samples were incubated with non-
reducing sample buffer, boiled for 5 min, and subjected to SDS-
PAGE.
Supporting Information
Figure S1 Carbohydrate processing, peptide binding of
transgenic MHCII molecules and stability of MHCII-Ii
complexes. A) MelJuSo cells were stably transfected with a V5-
tagged DPb encoding cDNA. The lysate of the DPb–transfected
MelJuSo cell clone was treated with PNGase F (lane 2), or with
EndoH (lane 3). The digested (lane 2 and 3) and non-digested (lane
1) lysates were immunoblotted for DPbV5 chain. B) Intracellular
transport of DRbV5 was monitored by digestion of cell lysate with
PNGase F (lane2), or with EndoH (lane 3). Non-digested cell lysate
was separated in lane 1. Lysates from non-transfected cells were
analyzed in lanes 4 to 6. SDS-PAGE separated lysates were blotted
for DRbV5 (lanes 1 to 3) and for DRb (lanes 4 to 6). C) Cell lysate
from DRbV5-transfected MelJuSo cells was incubated for 1 h in
SDS sample buffer at RT (lane 1). Lane 2 shows cell lysate boiled
for 5 min in SDS buffer. The SDS separated lysates were
immunoblotted for DRbV5. The position of the peptide-bound
DRabV5 heterodimer and of the dissociated DRbV5 chain is
indicated. D) MelJuSo (MJ) and MJDRbV5 cells were stained with
CD63-Alexa 488 and with V5 monoclonal antibodies and
examined by confocal-immunofluorescence microscopy. The left
panels show CD63 and the middle panels V5 staining. In the right
panel the two patterns were merged. E) MJDRaV5 cells were
lysed and immunoprecipitated with V5 mAb. The immunopre-
cipitate (lane 1) and the lysate (lane 2) were separated by SDS
PAGE and western blotted with mAb Bu43 for Ii (notice that cell
lysate contains DR-associated Ii and an excess of free Ii). The
position of Ii and of H and L chains of mAb V5 are shown on the
left. F) Raji cells were lysed in 1% digitonin and Ii was
immunoprecipitated with mAbs Vic-Y1 and Bu45. Immunopre-
cipitates were washed with digitonin buffer and incubated with 1%
Triton X-100. The immunoprecipitate (lanes 1 and 3) and the
Triton X-100 supernatant (lanes 2 and 4) were western blotted for
Ii (lanes 1 and 2) (mAb Bu43) and for DRa (lanes 3 and 4) (mAb
TAL-1B5). The positions of Ii, of DRa and of immunoglobulin H
and L chains are indicated by arrows.
(TIF)
Figure S2 Isolation of DRbV5 from transfected MelJuSo
cell lysates. A) Lysates from the DRbV5-transfected MelJuSo
cell line were immunoprecipitated for DRbV5 (monoclonal
antibody V5, lane 1), for DRbHis (monoclonal antibody His,
lane 2), for the DRab heterodimer (monoclonal antibody I251SB,
lane 3), and for DRa (monoclonal antibody TAL-1B5, lane 4).
Lysates from DRbV5 and from untransfected MelJuSo cells were
separated in lanes 5 and 6. Three parallel blots were immuno-
stained for DRb (S35, upper panel), for DRbV5 (monoclonal
antibodyV5, middle panel) and for DRa (monoclonal antibody
TAL-1B5, lower panel). Arrows indicate the positions of DRb,o f
DRbV5 and of DRa.B )D R bV5 and untransfected MelJuSo cells
(MJ) were lysed in 1% digitonin. DRab was immunoprecipitated
by the conformation-dependent mAb ISCR3. Immunoprecipitates
and cell lysates were SDS-PAGE separated and western blotted for
DRb (left panel, mAb LGII-612.14), for DRa (middle panel, mAb
TAL-1B5), or for Ii (right panel, mAb Bu43). The positions of
DRbV5, DRb,D R a and of Ii are indicated by arrows.
(TIF)
Text S1 Supplemental text.
(DOC)
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